Table 3.
Clinical outcomes evolution and response at month 12. Abbreviatures: Best Corrected Visual Acuity (BCVA), Central Foveal Thickness (CFT), Intraretinal Fluid (IRF), Subretinal fluid (SRF), Sub-Retinal pigmented epithelium fluid (sub-RPE fluid), Interquartile range (IQR).
| Variables | Total n = 37 |
Poor Responder 12 Months n = 20 (54%) |
Good Responder 12 Months n = 17 (46%) |
p-Value |
|---|---|---|---|---|
| BCVA at baseline (median, IQR) |
60 (43–70) | 58 (41–65) | 65 (45–71) | 0.292 * |
| BCVA at month 4 (Median, IQR) |
65 (55–75) | 65 (55–69) | 69 (60–77) | 0.264 ‡ |
| BCVA at month 12 (Median, IQR) |
71 (63–77) | 68 (62–76) | 72 (65–80) | 0.306 ‡ |
| CFT at baseline (Median µm, IQR) | 310 (267–364) | 341 (256–372) | 290 (270–345) | 0.503 ‡ |
| CFT at month 4 (Median µm, IQR) | 214 (200–250) | 220 (193–249) | 211 (203–250) | 0.737 ‡ |
| CFT at months 12 (Median µm, IQR) | 232 (212–274) | 235 (223–261) | 224 (205–275) | 0.503 ‡ |
| IRF at baseline (n, %) | 0.501 * | |||
| Absence | 13, 35% | 8, 40% | 5, 29% | |
| Present | 24, 65% | 12, 60% | 12, 71% | |
| IRF at month 4 (n, %) | 0.179 * | |||
| Absence | 29, 78% | 14, 70% | 15, 88% | |
| Present | 8, 22% | 6, 30% | 2, 12% | |
| IRF at month 12 (n, %) | 0.016 * | |||
| Absence | 28, 76% | 12, 60% | 16, 94% | |
| Present | 9, 24% | 8, 40% | 1, 6% | |
| SRF at baseline (n, %) | 0.383 * | |||
| Absence | 9, 24% | 6, 30% | 3, 18% | |
| Present | 28, 76% | 14, 70% | 14, 82% | |
| SRF at month 4 (n, %) | 0.917 * | |||
| Absence | 28, 76% | 15, 75% | 13, 76 | |
| Present | 9, 24% | 5, 25% | 4, 24% | |
| SRF at month 12 (n, %) | 0.179 * | |||
| Absence | 29, 78% | 14, 70% | 15, 88% | |
| Present | 8, 22% | 6, 40% | 2, 12% | |
| Sub-RPE fluid at baseline (n, %) | 0.160 * | |||
| Absence | 11, 30% | 4, 20% | 7, 41% | |
| Present | 26, 70% | 16, 80% | 10, 59% | |
| Sub-RPE fluid at month 4 (n,%) | 0.138 * | |||
| Absence | 26, 70% | 12, 60% | 14, 82% | |
| Present | 11, 30% | 8, 40% | 3, 18% | |
| Sub-RPE fluid at month 4 (n,%) | 0.498 * | |||
| Absence | 31, 84% | 16, 80% | 15, 88% | |
| Present | 6, 76% | 4, 20% | 2, 12% | |
| Fibrosis at baseline (n,%) | 0.622 * | |||
| Absence | 37, 100% | 20, 100% | 17, 100% | |
| Present | 0, 0% | 0, 0% | 0, 0% | |
| Fibrosis at month 4 (n,%) | 0.211 * | |||
| Absence | 32, 86% | 16, 80% | 16, 94% | |
| Present | 5, 14% | 4, 20% | 1, 6% | |
| Fibrosis at month 4 (n,%) | 0.856 * | |||
| Absence | 30, 81% | 16, 80% | 14, 82% | |
| Present | 7, 19% | 4, 20% | 3, 18% |
* Tested by Chi2, ‡ Non-normal distribution (tested by Shapiro–Wilk test), variable tested by Mann–Whitney test.